Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
August 4, 2022 6:00 AM EDTNet revenue increased to $28.2 million for Q2 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS® (voclosporin) for 2022
Continued increases in LUPKYNIS Patients on Treatment; Steady Conversion Rates and Payor Coverage
EMA review of LUPKYNIS remains on track with decision expected by the end of Q3 2022
$391.7 million of cash and investments as of June 30, 2022
Conference call to be hosted today at 8:30 a.m. ET
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:... More
